# OncoSELECT®
by OncoDNA

**OncoSELECT is a fast, minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colon, breast (ER+ or HER2+) cancer patients.**
**OncoSELECT is the perfect diagnostic tool when a targeted therapy is planned or being used.**

## WHEN & WHY PERFORM ONCOSELECT ?

### for a **COLORECTAL** cancer patient:

1. The patient has been diagnosed wild type for KRAS / NRAS / BRAF and is receiving anti-EGFR therapy and (s)he is resisting therapy —› Then apply OncoSELECT after a line of treatment, so the oncologist would be able to know if the patient acquired a mutation leading to this resistance.
2. The patient is either KRAS / NRAS / BRAF mutated and is receiving chemotherapy in neoadjuvant settings (before the surgery) —› Then apply OncoSELECT in first line before surgery, so the oncologist will be able to know if the patient is answering the treatment.
3. The patient is metastatic and wild type for KRAS / NRAS / BRAF based on the solid biopsy available —› Then apply OncoSELECT before the first line treatment, so the oncologists will be able to check the heterogeneity of the disease before starting the treatment.

### for a **LUNG** cancer patient:

1. The patient has not been treated yet. Then apply OncoSELECT before the first line treatment, so the oncologists will be able to check the heterogeneity of the disease before starting the treatment.
2. The patients is treated by targeted therapy since an activating mutation (EGFR) or translocation (ALK/ROS1) has been reported —› Then apply OncoSELECT after a line of treatment, so the oncologist would be able to know if the patient acquired a mutation leading to this resistance.
3. When the patient is metastatic and wild type for EGFR / BRAF based on the solid biopsy before 1st line —› Then apply OncoSELECT before the first line treatment, so the oncologists will be able to check the heterogeneity of the disease before starting the treatment.

### for a **BREAST** cancer patient:

1. The patients is treated by either hormonotherapy and/or anti-HER2. The patient is relapsing —› Then apply OncoSELECT after a line of treatment, so the oncologist would be able to know if the patient acquired a mutation leading to this resistance.
2. When the patient is getting worse during or after hormonotherapy, to know if the patient is eligible for Alpelisib —› Then apply OncoSELECT to know the PICKCA status of the patient.

**MATERIAL**

**2 blood samples** (2 Streck tubes of 10 ml each)

**CANCER-SPECIFIC LIQUID BIOPSY**

LIQUID BIOPSY

**Next-generation sequencing**

- Analysis of more than **100 mutations** of resistance and sensitivity to targeted therapies (SNV, Indels, translocation and CNV)
- Specific genes selected for each cancer type

**INTEGRATED THERANOSTIC REPORT**

Reporting of new variant(s) associated with resistance and/or nex treatment options.

OncoDNA Headquarters
1 Rue Louis Bréguet
6041 Gosselies - Belgium
+32 (0)71 18 35 00
infos@oncodna.com
www.oncodna.com

# GENE PANELS

for a **COLORECTAL** cancer:

## DNA

| GENE | CODONS / EXONS |
|---|---|
| NRAS | Codons : 12/13/59/61/117/146 |
| KRAS | Codons : 12/13/59/61/117/146 |
| AKT1 | Codon : 17 |
| MAP2K1 | Codons : 56/57/67 |
| CTNNB1 | Codons : 41/45 |
| PIK3CA | Codons : 542/545/546/1047 |

| GENE | CODONS / EXONS |
|---|---|
| EGFR | Codons : 451/467/464/465/491/468/492 |
| BRAF | Codons : 466/469/472/594/597/600 |
| SMAD4 | Exons : 3/4/5/6/8/9/10/11/12 |
| FBXW7 | Exons : 5/8/9/10/11 |
| ERBB2 | NA - CNV only |

for a **LUNG** cancer patient:

## DNA

| GENE | CODONS / EXONS |
|---|---|
| NRAS | Codons : 12/13/59/61/117/146 |
| KRAS | Codons : 12/13/59/61/117/146 |
| DDR2 | Codon : S768R |
| AKT1 | Codon : 17 |
| MAP2K1 | Codons : 56/57/67 |
| BRAF | Codons : 466/469/472/594/597/600 |

| GENE | CODONS / EXONS |
|---|---|
| ROS1 | Codons : L2155S/L2026M/G2032R/ D2033N/L1951R |
| MET | Codon : Y1230C |
| ALK | Exons : 21/22/23/24/25 |
| EGFR | Exons : 18/19/20/21 |
| ERBB2 | Exon : 20 |

for a **BREAST** cancer (Non Triple Negative):

## DNA

| GENE | CODONS / EXONS |
|---|---|
| ERBB2 | Codon : 309 |
| AKT1 | Codon : 17 |
| PIK3CA | Codons : 542/545/1047<br>Exons : 2/5/6/8/10/21 |
| mTOR | Exons : 19/30/39/40/43/44/45/47/48/53/56 |

| GENE | CODONS / EXONS |
|---|---|
| PTEN | Exons : 1/2/3/4/5/6/7/8/9 |
| ESR1 | Exons : 5/6/7/8 |
| FGFR1 | NA - CNV only |

OncoDNA Headquarters
1 Rue Louis Bréguet
6041 Gosselies - Belgium
+32 (0)71 18 35 00
infos@oncodna.com
www.oncodna.com